This page explains New Zealand’s system. Its licences, funding rules and prescribing criteria do not determine access in the UK.
Does a place on Pharmac's Options for Investment list mean funding is imminent?
No. Pharmac says it cannot promise when, or whether, a medicine will be funded.
Approved uses are documented
Medsafe's current Mounjaro data sheet includes chronic weight management for qualifying adults. Pharmac also confirms Medsafe approval of Wegovy and Mounjaro for weight management. Approval does not determine the price charged by a dispensing pharmacy.
Funding is still separate
Pharmac's 3 November 2026 update says both medicines remain unfunded. Wegovy weight-management applications are on its Options for Investment list. It reports a Mounjaro diabetes application but no application for Mounjaro weight-loss funding at that date.
Do not borrow diabetes eligibility
Funding for other GLP-1 medicines in qualifying people with type 2 diabetes does not establish obesity-treatment coverage. The indication remains essential when reading a country's access rules.
A useful boundary for UK readers
Pharmac does not control private prices for these unfunded medicines. An NZD price or favourable funding recommendation does not establish UK cost or access. For a UK decision, check the applicable NHS pathway or compare registered UK services and continuing GBP charges.
Keep these four questions separate
Access
New Zealand approved indications and prescribing
Funding
Wegovy and Mounjaro unfunded in Pharmac's November update
Cost context
Private NZD pricing does not establish UK cost
Regulatory source
Medsafe
Sources & further reading
Sources checked . These links support the information above; they do not imply endorsement of this website.
Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.
Read our editorial standards →
Compare prices